GENE ONLINE|News &
Opinion
Blog

2022-07-28| Special

BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies

by Reed Slater
Share To

Hundreds of biotech startups pop up yearly, and their fate typically has three options. They can flourish into successful independent companies of their own, shrink and shutter in failure, or, most likely, make an exit through a merger or acquisition to a larger company. 

Timothy K. Lu, Co-founder, and CEO of Senti Biosciences, Inc., moderated the panel “Exit Strategies for Early Stage New Drug Companies” at BIO Asia-Taiwan 2022, which began July 27 with the theme of “Connecting the Asian Value Chain.” The event brings together biotechnology, pharmaceutical executives, and investors worldwide to explore business opportunities in Taiwan’s emerging biotech sector. 

During the panel, five respected industry experts provided their thoughts on startup exit strategies and the considerations for maneuvering within the biotech industry. The panelists issued their opinions on the importance of an initial plan when starting a company, the opportunities and limitations of cross-border investments, and sufficient international patent protection in a globalized world. 

It's free! Log in now to read

LATEST
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top